TC-2216 is a drug developed by
Targacept which acts as a
partial agonist at neural
nicotinic acetylcholine receptors and was researched for the treatment of
anxiety and
depression.
It was unsuccessful as a therapeutic but is still used in pharmacological research as an alpha4beta2-selective antagonist.
References
{{Nicotinic acetylcholine receptor modulators
Nicotinic agonists
3-Pyridyl compounds
Spiro compounds